Cancer and Solid Organ Transplantation

Dear Colleagues,

The immune system, with its multiple pathways, links the amazing worlds of transplantation and cancer in terms of diagnosis, management, and treatment, especially in the era of precision medicine. As such, it is no surprise that there is great interest in the types of cancer that transplant patients may face in higher numbers compared to the non-immunosuppressed population, as well as in the increasing promise of transplant oncology as therapy for several types of cancer. In addition, the role and modulation of immunosuppression with the great variety of different medications and protocols is critical in the care of these patients. Significant breakthroughs in the field of immunotherapy have led to the rapid expansion of transplant oncology, where patients with types of cancers, such as metastatic hepatic disease from colorectal cancer, are now finding new hope in properly selected cases with liver transplantation.

We are pleased to invite clinicians, surgeons, and basic science and clinical researchers to contribute to this Special Issue where the aim is to discuss issues such as:

• Risk factors for new cancers after transplantation;
• The role of immunology in cancer and solid organ transplantation;
• Types of cancers in donors and how they affect the donation process;
• Management of immunosuppression in patients with cancer;
• Immunosuppression medications with oncological effect;
• Diagnosis and management of cancer after transplantation;
• The role of liver transplantation in the management of hepatocellular carcinoma;
• The evolving nature of transplant oncology;
• The role of liver transplantation in the management of cholangiocarcinoma;
• The role of liver transplantation in the management of hepatic metastatic disease, including metastasis from neuroendocrine lesions and colorectal cancer;
• Adapting immunosuppression in a patient with cancer after transplantation;
• Evaluating donors with a cancer history;
• Psychosocial support of the transplant patient with a malignancy;
• Cancer in transplant patients in the age of artificial intelligence.

In this Special Issue, original research articles and reviews are welcome. We are looking forward to your contributions.

Dr. Georgios Tsoulfas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.